NVCT Nuvectis Pharma, Inc.
Financings ·
Nuvectis can sell up to $60 million of stock through Leerink. It ended an earlier $40 million program with H.C. Wainwright after selling about $18.6 million under it.
We have not published a story on Nuvectis Pharma yet. When there is news, it will appear here.
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions with unmet medical need. Its lead product candidate, NXP900, is a targeted small molecule that inhibits the SRC and YES1 kinases, which the company says it licensed worldwide commercial rights to in August 2021 from the University of Edinburgh. The FDA cleared the Investigational New Drug application for NXP900 in May 2023, with a Phase 1 protocol in two parts: a dose-escalation Phase 1a and an expansion Phase 1b. In July 2025 the company completed the Phase 1a part, in which a dose range of 20 to 300 mg/day was evaluated and the dose-limiting toxicity level was not reached. A pharmacodynamic response of approximately 90% inhibition of SRC kinase phosphorylation was seen at doses of 150 mg/day and higher. The Phase 1b expansion began in August 2025 and will evaluate NXP900 as a single agent in specific tumor types and in combination with EGFR and ALK inhibitors. The company's text notes SRC is aberrantly activated in breast, colon, prostate, pancreatic and ovarian cancers and that no FDA-approved selective YES1 inhibitor exists.
| Product or program | What it is | Stage |
|---|---|---|
| NXP900 | Targeted small molecule inhibiting SRC and YES1 kinases for solid tumors | Phase 1b expansion initiated August 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $18.2 million | $12.9 million |
| Net income (loss) | -$26.4 million | -$19.0 million |
| Cash from operations | -$16.0 million | -$12.2 million |
| Cash and equivalents | $31.6 million | $18.5 million |
Opinion Mixed view
A July offering added about $106.3 million net, and $20.0 million of it went to Haisco for two more early drugs. The company says it can fund planned operations for at least 12 months, and that it needs more money to finish its trials.
Our latest story on this, dated May 9, 2025: "Nuvectis Pharma sets up $60 million at-the-market stock program with Leerink". The story links the filing or release it is based on. Read the story.
Nuvectis Pharma, Inc. trades under the ticker NVCT on NASDAQ.
Nuvectis Pharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Nuvectis Pharma, Inc. is 1875558. Its filings are on SEC EDGAR.
32,581,533 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04.
Our directory records Nuvectis Pharma, Inc. under United States.
Our directory classifies Nuvectis Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Nuvectis Pharma, Inc. is US67080T1088.
aibio.space lists Nuvectis Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions with unmet medical need. Its lead product candidate, NXP900, is a targeted small molecule that inhibits the SRC and YES1 kinases, which the company says it licensed worldwide commercial rights to in August 2021 from the University of Edinburgh.
NXP900: Targeted small molecule inhibiting SRC and YES1 kinases for solid tumors Stage: Phase 1b expansion initiated August 2025.
Nuvectis Pharma, Inc. reported a net loss of $26.4 million for the fiscal year ended Dec 31, 2025, and used $16.0 million of cash in operations, per its annual report to the SEC.
$18.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$22.2 million in cash at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio